



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Bao Leyuan has been appointed as executive Director of the Company with effect from 1 September, 2008.

The Board of Directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) is pleased to announce that Mr. Bao Leyuan has been appointed as executive Director with effect from 1 September, 2008.

The details of Mr. Bao Leyuan as required under Rule 13.51(2) of The Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) are set out below.

Mr. Bao Leyuan (包樂源), aged 51, is currently a director of Xi'an Rejoy Group Co., Ltd., Xi'an Lijun Fangyuan Pharmaceutical Co., Ltd. and Shaanxi Lijun Modern Traditional Chinese Medicine Co., Ltd.. Mr. Bao joined Xi'an Lijun Pharmaceutical Co., Ltd., a subsidiary of the Company, as a vice chief accountant since 1997. He has also acted as the chief operations officer of the Company responsible for the asset management functions of our Group since 2006. Mr. Bao graduated from Xi'an Radio and Television University in 1986. He is also a qualified accountant in China and has ample experience in financial management. Mr. Bao has not held any directorship in any listed public companies in the last three years.

Mr. Bao has entered into a service contract with the Company for a fixed term of three years commencing from 1 September, 2008, subject to retirement and re-election provisions as set out in the Company's articles of association. Pursuant to the service contract, the annual director's emoluments of Mr. Bao is HK\$300,000 with discretionary bonus based on the Company's performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Mr. Bao's qualification and experience, as well as the responsibilities to be undertaken. In addition, Mr. Bao is eligible to participate in the Company's share option scheme. Save as disclosed above, Mr. Bao does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

As at the date of this announcement, Mr. Bao was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules nor is there any other matter which needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its warm welcome to Mr. Bao on his joining the Board.

On behalf of the Board

Wu Qin

Chairman

Hong Kong, 1 September, 2008

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Huang Chao, Mr. Xie Yunfeng, Ms. Sun Xinglai, Mr. Wang Xianjun, Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu and Mr. Bao Leyuan as executive Directors, Mr. Liu Zhiyong as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.